Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.43 EPS (ttm)2.91 Insider Own9.30% Shs Outstand2.51B Perf Week-1.15%
Market Cap221.95B Forward P/E15.61 EPS next Y5.66 Insider Trans-0.81% Shs Float2.51B Perf Month-3.86%
Income6.79B PEG3.82 EPS next Q1.32 Inst Own11.50% Short Float0.12% Perf Quarter1.05%
Sales50.21B P/S4.42 EPS this Y66.90% Inst Trans-4.86% Short Ratio1.49 Perf Half Y8.38%
Book/sh22.26 P/B3.97 EPS next Y10.43% ROA8.40% Target Price101.00 Perf Year17.98%
Cash/sh4.12 P/C21.48 EPS next 5Y7.97% ROE17.80% 52W Range72.70 - 95.00 Perf YTD15.06%
Dividend2.83 P/FCF45.53 EPS past 5Y7.70% ROI11.50% 52W High-6.91% Beta0.59
Dividend %3.20% Quick Ratio0.70 Sales past 5Y0.20% Gross Margin70.10% 52W Low21.64% ATR1.48
Employees108000 Current Ratio0.90 Sales Q/Q3.40% Oper. Margin16.20% RSI (14)41.09 Volatility1.06% 1.39%
OptionableYes Debt/Eq0.59 EPS Q/Q-72.60% Profit Margin22.70% Rel Volume0.89 Prev Close89.00
ShortableYes LT Debt/Eq0.43 EarningsJul 18 BMO Payout59.60% Avg Volume2.07M Price88.44
Recom1.50 SMA20-2.26% SMA50-2.89% SMA2006.13% Volume1,837,035 Change-0.63%
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Aug-22-19 02:37PM  Novo Nordisk's Fiasp Gets EC Approval for Label Expansion Zacks
Aug-21-19 03:23PM  David Rolfe Adds 4 Stocks to Portfolio in 2nd Quarter GuruFocus.com
11:50AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
11:04AM  Teva Launches Generic Version of Mylan's EpiPen for KIds Zacks
10:49AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS) ACCESSWIRE
Aug-20-19 04:00PM  Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
03:06PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:42PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
Aug-19-19 06:09PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
03:58PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG NVS Business Wire
02:21PM  5 Companies Still Run by Families Motley Fool
08:04AM  AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA Zacks
06:00AM  5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool
03:20AM  Novartis to answer U.S. Senate demand for data manipulation details Reuters
01:00AM  Novartis executive sold almost $1m shares ahead of FDA probe Financial Times
Aug-18-19 12:18PM  Novartis executive sold shares before drug data manipulation made public Reuters
11:27AM  Novartis exec sold shares before drug data manipulation made public Reuters
Aug-16-19 01:10PM  A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis Motley Fool
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-15-19 05:27PM  Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future American City Business Journals
09:17AM  Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat Zacks
Aug-14-19 11:27PM  Novartis replaces top scientists at Avexis after drug data manipulated Reuters
08:57PM  PRESS DIGEST- Financial Times - Aug 15 Reuters
03:00PM  Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data Investor's Business Daily
11:09AM  UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated Reuters
10:58AM  Everyones Mad At Novartis. But the Stock Is Doing Just Fine Barrons.com
10:34AM  Novartis replaces top scientists at Avexis after drug data manipulated Reuters
09:37AM  Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80% Zacks
09:36AM  Wednesdays Vital Data: Amgen, American Airlines and Apple InvestorPlace
09:24AM  Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study Zacks
08:54AM  Novartis names Bulto as new head of U.S. drugs business Reuters
07:37AM  Novartis ousted scientists before reporting drug data manipulation Financial Times
Aug-13-19 04:45PM  Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales Investor's Business Daily
11:12AM  Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate Zacks
10:48AM  Here's Why Amgen Stock is Outperforming Its Industry Of Late Zacks
06:00AM  5 Biggest New Drugs Approved in 2019 So Far Motley Fool
Aug-12-19 06:05PM  UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues Reuters
05:27PM  Senator Grassley seeks info on Novartis's Zolgensma data issues Reuters
04:18PM  The Biggest Biotech Stock Is Approaching A Breakout Here's Why Investor's Business Daily
02:21PM  Amgen stock gets boost from Friday ruling on Enbrel MarketWatch
09:44AM  Amgen Wins Enbrel U.S. Patent Litigation Against Novartis Zacks
09:31AM  Amgens Court Win Could Mark a New Dawn for the Stock Barrons.com
09:07AM  [video]Amgen Climbs After Winning Patent Case on Enbrel TheStreet.com
05:00AM  5 Big Pharma Showdowns to Watch Barrons.com
Aug-11-19 02:03PM  5 Reasons Novartis Shareholders Aren't Shaken Motley Fool
05:00AM  Novartis benefits from faster China drug approvals Financial Times
Aug-09-19 10:59AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2 Zacks
10:42AM  Tilray (TLRY) to Report Q2 Earnings: What's in the Cards? Zacks
09:30AM  Has Novartis (NVS) Outpaced Other Medical Stocks This Year? Zacks
Aug-08-19 04:26PM  Sarepta stock tumbles after Duchenne gene therapy complication American City Business Journals
09:30AM  NVS vs. NVO: Which Stock Should Value Investors Buy Now? Zacks
Aug-07-19 11:28PM  Medicare to cover expensive cancer cell therapies Reuters
09:30PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
07:42PM  Novartis (NVS) Alert: Johnson Fistel Launches Investigation into Novartis AG; Investors Encouraged to Contact Firm PR Newswire
07:20PM  2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond Zacks
07:05PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
06:36PM  UPDATE 1-Medicare to cover expensive cancer cell therapies Reuters
04:31PM  Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses Investor's Business Daily
01:37PM  Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold Zacks
11:00AM  Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies Zacks
10:40AM  FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma Benzinga
10:12AM  UPDATE 2-Novartis says it knew of Zolgensma data problems before U.S. approval Reuters
09:30AM  Novartis says knew about Zolgensma data problems before U.S. approval Reuters
08:24AM  Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Call Transcript Motley Fool
07:34AM  The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout Benzinga
03:49AM  [video]FDA Says Some Data From Novartis Gene Therapy Manipulated TheStreet.com
Aug-06-19 08:03PM  PRESS DIGEST- Financial Times - Aug 7 Reuters
06:36PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG GlobeNewswire
04:19PM  Novartis $2.1 Million Gene Therapy Is Based On Flawed Data, Says FDA Investor's Business Daily
02:30PM  U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated Reuters
02:28PM  UPDATE 2-FDA says some data testing Novartis' $2 mln gene therapy was manipulated Reuters
02:27PM  Novartis stock falls after FDA says Zolgensma BLA had a 'data manipulation issue' MarketWatch
01:41PM  FDA says some data testing Novartis' $2 mln gene therapy was manipulated Reuters
03:06AM  FDA probing data manipulation from early tests of Novartis drug Financial Times
Aug-05-19 10:46AM  Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates Zacks
Aug-02-19 09:54AM  Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger Zacks
05:00AM  Biogen on the brink: One of the state's largest drugmakers faces a crisis American City Business Journals
Aug-01-19 09:49AM  United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y Zacks
Jul-31-19 10:44AM  Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat Zacks
09:55AM  Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised Zacks
Jul-30-19 05:40PM  Big drugmakers trade Peninsula plant as part of larger deal American City Business Journals
01:06PM  Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y Zacks
01:04PM  Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up Zacks
09:14AM  Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y Zacks
09:10AM  Are Investors Undervaluing Novartis (NVS) Right Now? Zacks
09:02AM  Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y Zacks
06:06AM  Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments Reuters
06:00AM  FOCUS-Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments Reuters
Jul-29-19 05:58AM  Novartis heart drug fails trial, curbing growth prospects Reuters
Jul-27-19 12:20PM  10 Biggest Cancer-Fighting Stocks Motley Fool
05:13AM  Novartis CEO pledges not to sell Sandoz generics unit Reuters
Jul-26-19 10:03AM  Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings? Zacks
09:15AM  S&P Stays Above 3,000 as Market Pulls Back Zacks
07:00AM  Dianne Feinsteins Husband Richard Blum Switches to Selling FedEx Stock From Buying Barrons.com
Jul-25-19 03:56AM  Astra, Roche Join Rivals in Boosting Forecasts as New Drugs Prosper Bloomberg
Jul-23-19 10:42AM  Biogen downplays premature talk of competition for SMA drug Spinraza American City Business Journals
09:56AM  Biogens Good Quarter Delays Drugmakers Future Reckoning Bloomberg
08:39AM  Biogens Earnings Beat Forecasts, but 1 Key Drug Fell Short Barrons.com
Jul-22-19 11:20AM  The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis Zacks
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; Verily; and Pharming Group N.V. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM